Content area
Full text
A message from the editor in chief
Images ]]>
Founding Editor in ChiefMarc B. Garnick, M.D.
Every year brings remarkable advances in the management and treatment of prostate diseases. With this, the 2022 Annual Report on Prostate Diseases, we once again bring you up to date on the most signi]]>
Especially noteworthy is regulatory approval of two imaging agents that reveal where new metastatic prostate tumors are growing in the body. These injectable compounds travel via the bloodstream until they encounter a protein on cancer cell s]]>]]>Genetic testing is another key area where important advances are being made. Scientists in 2021 identified close to 90 additional genetic mutations that increase a man’s inherited risk of developing prostate cancer. Clinicians increasingly rely on genetic tests to guide cancer treat]]>
Hormonal therapy (also called androgen deprivation therapy) is a mainstay of prostate cancer treatment. We cover the latest news on cardiovascular complica]]>
In addition, we include a roundtable discussion on exciting developments in treating oligometastatic prostate cancer, which was formerly regarded as incurable, but now in some instances can be considered curable.
Finally, we provide the latest news about benign prostatic hyperplasia, prostatitis, and erectile dysfunction.
We hope you find this edition of the Annual to be helpful. We also encourage you to read our 2017 companion publication, Patient Perspectives on Prostate Diseases, in which men recount their experiences with many of the treatments described in the Annual. We are pleased to be completing our 16th year of publication and look forward to many more years ahead of providing this timely information for our dedicated and expanding readership.
Images
Marc B. Garnick, M.D.Founding Editor in Chief, 2022 Annual Report on Prostate Diseases
| For more information on the Harvard Special Health Report Patient Perspectives on Prostate Diseases, go to www.health.harvard.edu/ps. |
What made news in 2021
The past year gave rise to many impressive developments in prostate research. Take, for instance, the FDA’s approval of new imaging agents, called tracers, used for locating cancer cells that might otherwise evade detection while spreading through the body. These tracers open up new avenues for treating metastatic prostate cancer in its earliest stages, when cures are still within reach.
Hormonal...